← dso_drift_severe (all companies) · CRDF (all signals) · all methodology

dso_drift_severe on Cardiff Oncology, Inc. (CRDF)

SIC 2836 — Biological Products, (No Diagnostic Substances) · CIK 1213037 · default direction: short

Definition

Fires on Days Sales Outstanding rising >25% YoY while revenue grows <10%. Channel-stuffing / receivables-quality precursor.

Every time the signal fired on CRDF

FYFiling dateEvent date1d5d20d60d252d
FY20222023-03-022023-03-02+1.73%+4.05%-4.62%-4.05%+101.73%
FY20212022-02-242022-02-24+7.49%-10.49%-3.00%-52.06%-38.58%
FY20192020-02-272020-02-27+11.38%+17.07%-17.89%+67.48%+740.65%
FY20182019-03-062019-03-06+30.70%+35.76%+20.25%-8.86%-54.43%

Forward returns are stock returns from event date (next trading day after filing). Sign is raw stock direction; the trade direction is in the calibration table below.

Universe-wide calibration (this signal across all companies)

Horizonn eventsGross stock retHit rateTrade dirNet PnLCost (bps)r/σ net
1d2,382+0.25%+44.16%short-0.49%35-0.04
5d2,381-0.30%+44.18%short+0.11%36+0.01
20d2,351+2.47%+43.26%short-2.54%40-0.02
60d2,258+16.34%+45.44%short-11.34%51-0.06
252d2,213+32.55%+49.30%short-24.65%102-0.10

Net PnL is direction × stock return − round-trip execution cost (5 bps half-spread + ADV-tiered borrow). See dso_drift_severe methodology for the full audit.


Data: /api/company/1213037/financials